Empagliflozin – SGLT2 Inhibitor for Diabetes and Cardiovascular Health

Empagliflozin is a highly selective and potent oral inhibitor of sodium-glucose co-transporter 2 (SGLT2). The drug represents a new generation of hypoglycemic agents whose mechanism of action is independent of insulin secretion or tissue sensitivity to it. Empagliflozin has fundamentally changed the approach to diabetes therapy by demonstrating pronounced cardioprotective and nephroprotective properties.

The drug's mechanism of action is based on the suppression of glucose reabsorption in the proximal tubules of the kidneys. SGLT2 is the primary transporter responsible for returning glucose from the renal filtrate back into the bloodstream. By blocking this protein, empagliflozin promotes the excretion of excess glucose in the urine (glucosuria), which leads to a direct reduction in plasma glucose levels. Additionally, the drug induces moderate osmotic diuresis and natriuresis, contributing to lower blood pressure and reduced myocardial preload. These processes help slow the progression of chronic kidney disease and significantly reduce the risk of hospitalization for heart failure.

The drug is taken once daily and works effectively both as monotherapy and as part of complex treatment regimens for diabetes and cardiovascular diseases.

Wikipedia page
Empagliflozin

Indications

Empagliflozin is indicated for use in adult patients for the following clinical conditions:

  • Type 2 Diabetes Mellitus: glycemic control (as an adjunct to diet and exercise) both as monotherapy and in combination with metformin, sulfonylureas, or insulin.
  • Cardiovascular Risks: reduction of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.
  • Heart Failure: treatment of symptomatic chronic heart failure (both with reduced and preserved ejection fraction) to reduce the risk of hospitalizations.
  • Chronic Kidney Disease (CKD): therapy for adults with CKD to slow the decline of kidney function and the risk of reaching end-stage renal disease.

Dosage and administration

The dosing regimen for empagliflozin is simple, but it requires consideration of the patient's renal function.

  • Standard Dose: the recommended starting dose is 10 mg once daily.
  • Maximum Dose: if well tolerated and stricter glycemic control is required, the dose may be increased to 25 mg once daily.
  • Administration: the tablet is taken orally, swallowed whole with water. It can be taken with or without food.
  • Renal Function Limitations: the drug's efficacy decreases with severe renal impairment. It is not recommended to start therapy if the estimated glomerular filtration rate (eGFR) is below 20–30 mL/min/1.73m².
  • Elderly Patients: no dose adjustment is required based on age, but regular monitoring of renal function is essential.

The use of empagliflozin is restricted in the presence of the following factors and conditions:

  • Hypersensitivity: known allergy to empagliflozin or any excipient in the tablet formulation.
  • Severe Renal Impairment: end-stage renal disease or patients on hemodialysis.
  • Pregnancy and Lactation: use during the second and third trimesters of pregnancy is contraindicated; safety data for breastfeeding are not available.
  • Type 1 Diabetes: the drug is not intended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
  • Acute Conditions: dehydration, severe infections, or conditions requiring emergency hospitalization.

Empagliflozin therapy may lead to the development of specific side effects related to its mechanism of action:

  • Genitourinary Infections: vulvovaginitis and balanitis (fungal infections) are most common, caused by the increased glucose content in the urine.
  • Diuretic Effect: increased frequency of urination (pollakisuria), which may lead to reduced circulating blood volume and hypotension.
  • Diabetic Ketoacidosis: a rare but serious complication that can occur with normal blood sugar levels (euglycemic ketoacidosis).
  • Skin Reactions: pruritus (itching), rash, or urticaria are observed rarely and are usually mild.
  • Laboratory Changes: slight increases in serum creatinine, hematocrit, and lipids may occur.
  • Hypoglycemia: the risk of critically low blood sugar increases only when used concomitantly with insulin or sulfonylureas.

Frequently Asked Questions

Empagliflozin is a selective inhibitor of sodium-glucose co-transporter 2 (SGLT2). It works in the kidneys by blocking the reabsorption of glucose into the bloodstream. As a result, excess sugar is simply eliminated from the body through urine. This mechanism is independent of insulin production or insulin sensitivity, making the drug effective at various stages of diabetes.
Beyond managing diabetes, empagliflozin offers significant cardio- and nephroprotective effects. It substantially reduces the risk of hospitalization for heart failure and slows the progression of chronic kidney disease. The drug helps remove excess fluid and salt, thereby decreasing the workload on the cardiovascular system and lowering blood pressure.
Because empagliflozin increases glucose excretion through the urinary tract, it creates an environment conducive to the growth of bacteria and fungi. Patients may experience an increased risk of genital infections (such as yeast infections) or urinary tract infections. Maintaining good personal hygiene and staying well-hydrated help minimize these risks.
Ketoacidosis is a rare but serious condition characterized by the buildup of ketones in the blood. A specific risk with empagliflozin is that ketoacidosis can occur even when blood sugar levels are near normal (euglycemic ketoacidosis). If symptoms like nausea, vomiting, abdominal pain, unusual thirst, or a fruity breath odor develop, seek medical attention immediately.
Empagliflozin is typically taken once daily, preferably in the morning. It can be taken with or without food. Taking it in the morning is recommended because the drug has a mild diuretic effect; doing so helps avoid the need for frequent urination during the night.

List of medicines by active substance

-15%
Glyxambi 10 mg / 5 mg Boehringer Ingelheim
View
Boehringer Ingelheim

Glyxambi

Empagliflozin + Linagliptin
10 mg / 5 mg 10 tablets
5169₴ 6067₴
✅ All products loaded (1)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00